联系我们

电话: 020-32299997

传真: 020-32290284

邮箱: gzlbp@126.com

首页 > 走进安必平 > 企业简介


       
广州安必平医药科技股份有限公司位于广州科学城,拥有医学、生物学、分析化学、机械自动化控制等跨学科的高级技术人员组成的研发团队,专注病理诊断产品的研发生产与服务。
 
       公司从二OO五年成立至今,通过与卫生部生物医药工程技术研究中心及中山大学等科研单位合作,历年来承担了国家科技部中小企业创新基金,国家高技术研究发展计划(863计划) 及各级政府的科研项目共16项,已取得各项专利30项,正在申报专利6项。获得了高新技术企业认定,软件企业认定和ISO13485认定。
 
       病理诊断从早期显微镜下的形态学诊断发展到今天的分子基因诊断,为当今临床医学最前沿的个性化诊断与个性化治疗提供了必要条件,市场前景广阔。安必平公司通过自主研发创新及与国际病理诊断领域的一流企业合作,形成了病理诊断试剂及配套设备全系列产品,包括液基细胞学试剂及配套仪器、免疫组织化学和分子病理诊断,这些产品梯度在国内企业中仅此一家。尤为突出的是,在分子病理诊断领域,我们产品覆盖了荧光原位杂交(FISH)产品系列、点突变基因检测系列,及正在研发中的高通量测序领域。此三项技术代表着未来临床及病理诊断的发展方向,代表着当今医学科学的前沿。随着中国医药集团医疗健康投资管理有限责任公司和中山大学达安基因股份有限公司等的投资加盟,我们正努力把安必平公司建设成为我国医学病理诊断行业的领先者。

                                       我们相信:病理诊断推动医疗进步!

    LBP Medicine Science & Technology Co., Ltd is located in Guangzhou Science City. It is a high-tech biomedical enterprise focusing on research & development. Its R & Dteam has senior interdisciplinary technical staffs, which is composed of medicine,biology, analytical chemistry and mechanical automation control. LBP Company focuses on R & D and production of the pathological diagnosis and services.
 
    Since established at 2005, LBP has been in cooperation with the Biomedicine Engineering Research Center of the Ministry of Health, the Sun Yat-sen University and other research units, and over the years has been assumed a total of 16projects, including the State Ministry of Science and Technology Innovation Fund for SMEs, the National High Technology Research and Development Program (863 Program) and all levels of government research projects. Until now, LBP has been obtained 30 patents , and are applying for 6 more patents. Moreover, LBP has passed the high-tech enterprises and the software companies and ISO13485 certification.
 
    From the early microscope morphological diagnosis to the molecular genetic diagnosis, nowadays, pathological diagnostic techniques has been provided the necessary conditions for a broad market prospect of clinical personalized diagnosis and treatment. 
 
    Depending on its independent research and innovation, and through cooperation with the international field of pathological diagnosis, LBP has already covered a full range of pathological diagnostic reagents and ancillary equipments, including liquid-based cytology, immunohistochemistry, and molecular genetic diagnosis. 
 
    Through participated with the investment of China National Pharmaceutical Group Healthcare Investment Management Co., Ltd. and Sun Yat-sen Da An Gene Co., Ltd., we are doing our best for LBP Company to become the leader of the pathological diagnosis industry in China.
 
     We believe that pathological diagnosis ensure promotes medical advances!
                                                                                                      
友情链接